HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences’ arm launches first veterinary approved generic of Furosemide Tablets
Sep-16-2025

Zydus Lifesciences’ step down wholly owned subsidiary -- ZyVet Animal Health has launched first veterinary approved generic of Furosemide Tablets, a critical therapy for managing congestive heart failure and chronic fluid retention in dogs and cats.

Furosemide remains the most widely used veterinary diuretic for reducing edema and pulmonary congestion due to cardiac, renal, or systemic disease. ZyVet’s formulation offers veterinarians a consistent, cost-effective solution that supports long-term therapy, without compromising dosing flexibility or product availability.  Manufactured under stringent quality standards, ZyVet’s Furosemide tablets are available in multiple strengths to accommodate patient-specific dosing. As with all ZyVet products, the new formulation reflects the company’s commitment to providing veterinarians and pet owners with much needed alternatives to higher-cost pioneer drugs. 

ZyVet’s expanding product portfolio supports a growing paradigm shift in the veterinary pharmaceutical market, where access to generic options remains limited despite increasing demand. Fewer than 20% of products in animal health have generic equivalents - yet the need for affordable, high-quality products is growing. With Furosemide, ZyVet launches another first to market veterinary generic pharmaceutical and strengthens its rapidly growing presence in the animal health pharmaceutical market. 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

  RELATED NEWS >>